Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective.
Lung cancer (Amsterdam, Netherlands)（2023）
摘要
Atezolizumab after adjuvant chemotherapy is cost-effective for adults with NSCLC in the UK.
更多查看译文
关键词
Adjuvant treatment,Atezolizumab,Cost-effectiveness,Immunotherapy,Non-small cell lung cancer,PD-L1 expression
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要